Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAIR: Aflibercept T&E in Japanese wAMD
NCT02305238Phase 4Completed
- Sponsor
- Bayer
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in exudative macular degeneration, sponsored by Bayer. Started Dec 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02305238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305238.